Skip to main content
SpringerLink
Log in

Polychemotherapy of Gastric Carcinoma

  • Conference paper
Gastric Carcinoma

  • 52 Accesses

Abstract

Gastric carcinoma is the second leading cause of death due to malignant neoplasias in the Federal Republic of Germany; 28 deaths per 100,000 inhabitants are recorded every year.1

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Causes of Death 1983, in Federal Office of Statistics, Wiesbaden: Gesundheitswesen, Series 12. Stuttgart, W. Kohlhammer, 1984, p. 12.

    Google Scholar 

  2. UICC: Spiesse B, Hermanek P, Scheibe O, et al (eds): TNM-Atlas. Berlin-HeidelbergNew York, Springer, 1985, p. 90.

    Google Scholar 

  3. Diehl JT, Herrmann RE, Cooperman AM, et al: Gastric carcinoma. A ten year review. Ann Surg 1983; 198: 9.

    Article  PubMed  CAS  Google Scholar 

  4. Bengmark S. Jeppson B: Staging of liver metastases, in Wess L, Gilberg HA (eds): Liver Metastases. Boston, GK Hall, 1982, p. 268.

    Google Scholar 

  5. Koyama Y, Sugimachi K. Soejima K: Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981; 5: 241.

    Article  Google Scholar 

  6. Nekajima T, Harashima S, Hirata M: Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol 1978; 22: 225.

    Google Scholar 

  7. De Lisi V, Cocconi G, Tonato M, et al: Randomized comparison of 5-FU alone or combined with carmustine, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treat Rep 1986; 70: 481.

    PubMed  Google Scholar 

  8. O’Connell MJ: Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 1985; 3: 1032.

    PubMed  Google Scholar 

  9. Borchard F, Sons HU: Klassifizierung des Magenkarzinoms aus pathologisch-anatomischer Sicht. Therapiewoche 1985; 35: 161.

    Google Scholar 

  10. Clarke JS, Cruze K, El Farra S, et al: The natural history and results of surgical therapy for carcinoma of the stomach. An analysis of 250 cases. Am J Surg 1961; 102: 143.

    Article  PubMed  CAS  Google Scholar 

  11. Dupont JB, Lee JR, Burton GR, et al: Adenocarcinoma of the stomach: review of 1497 cases. Cancer 1978; 41: 941.

    Article  PubMed  Google Scholar 

  12. Walther H: Krebsmetastasen. Basel, Schwabe, 1948, p 363.

    Google Scholar 

  13. Warren S: Studies on tumor metastasis: IV. Metastases of cancer of the stomach. N Engl J Med 1933; 209: 825.

    Article  Google Scholar 

  14. Warwick M: Analysis of one hundred and seventy-six cases of carcinoma of the stomach submitted to autopsy. Ann Surg 1928; 88: 216.

    Article  PubMed  CAS  Google Scholar 

  15. Moertel CG, Lavin PT: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1863.

    PubMed  CAS  Google Scholar 

  16. The Gastrointestinal Tumor Study Group: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1871.

    Google Scholar 

  17. Bruckner HW, Lokich JJ, Stablein DM: Studies of Bakers antifol, methotrexate and Razoxane in advanced gastric cancer. A Gastrointestinal Tumor Study Group Report. Cancer Treat Rep 1982; 66: 1713.

    PubMed  CAS  Google Scholar 

  18. Aabo K, Pedersen H, Rorth M: Cisplatin in the treatment of advanced gastric carcinomas: a phase II study. Cancer Treat Rep 1985; 69: 449.

    PubMed  CAS  Google Scholar 

  19. Beer M, Cocconi G, Ceci G, et al: A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983; 19: 717.

    Article  PubMed  CAS  Google Scholar 

  20. Kantarjian H, Ajani JA, Karlin DA: Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 1985; 42: 69.

    Article  PubMed  CAS  Google Scholar 

  21. Lacave AJ, Wils H, Bleiberg E, et al: Advanced and chemotherapy-resistant gastric cancer (GC): benefit of additional MeCCNU (Me) and evaluation of CDDP (P), abstract. EORTC Symposium on Gastrointestinal Tract Cancer, Heidelberg, May 29–30, 1986.

    Google Scholar 

  22. Lacave AJ, Wils J, Diaz-Rubio E, et al: Phase II study of cisplatin (DDP) in chemotherapy resistant carcinoma of the stomach. Cancer Chemother Pharmacol 1985; 14 (suppl): 39.

    Google Scholar 

  23. Perry MC, Green MR, Mick R, et al: Cisplatin in patients with gastric cancer: a cancer and leukemia group B phase II study. Cancer Treat Rep 1986; 70: 415.

    PubMed  CAS  Google Scholar 

  24. Preusser P, Achterrath W, Niederle N, et al: Cisplatin. Arzneimitteltherapie 1985; 2: 50.

    Google Scholar 

  25. Bedikian AY, Chen TT, Khankhanian N, et al: The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 1984; 2: 305.

    PubMed  CAS  Google Scholar 

  26. Bleiberg H: Prognostic significance of pathological staging in gastrointestinal tumors. Eur J Cancer Clin Oncol 1985; 21: 655.

    Article  PubMed  CAS  Google Scholar 

  27. Bruckner HW, Stablein DM: Sites of treatment failure: Gastrointestinal Tumor Study Group analyses of gastric, pancreatic, colorectal trials. Cancer Treat Rep 1983; 2: 199.

    Google Scholar 

  28. Lavin PT, Bruckner HW, Plaxe SC: Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 1982; 50: 2016.

    Google Scholar 

  29. MacDonald JS, Schein PS, Woolley PV, et al: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination-chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533.

    PubMed  CAS  Google Scholar 

  30. Queisser W, Flechtner H, Heim ME, et al: 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) for advanced gastric carcinoma, a phase II trial. J Cancer Res Clin Oncol 1986; 111 (suppl): 85.

    Article  Google Scholar 

  31. Kim RH, Huh K, Ahn Y, et al: BCNU, cisplatin and 5-fluorouracil polychemotherapy in advanced gastric cancer. Proc ASCO 1985; 4: 95.

    Google Scholar 

  32. Kim RH, Kim CS: Chemotherapy of advanced gastric cancer with mitomycin C, BCNU, cisplatin and 5-fluorouracil in combination. Proc ASCO 1986; 5: 78.

    Google Scholar 

  33. Schein PS, Coombes RC, Chilvers C: For the international adjuvant trial in gastric cancer. A controlled trial of FAM (5-FU, doxorubicin, and mitomycin C) chemotherapy as adjuvant treatment for resected gastric carcinoma: an interim report. Proc ASCO 1986; 5: 79.

    Google Scholar 

  34. Galiano R, McCracken JD, Chen T: Adjuvant chemotherapy with 5-fluorouracil, Adriamycin, and mitomycin (FAM) in gastric cancer. Proc ASACO 1983; 2: 114.

    Google Scholar 

  35. Imanaga H, Nakazato H: Results of surgery for gastric cancer and effect of adjuvant mitomycin-C on cancer recurrence. World J Surg 1977; 1: 213.

    Article  Google Scholar 

  36. Koyama Y: The current status of chemotherapy for gastric cancer in Japan with special emphasis on mitomycin-C. Rec Res Cancer Res 1978; 63: 135.

    CAS  Google Scholar 

  37. Asakawa H, Otawa K, Watari J: High energy x-ray therapy for stomach carcinoma, second report: the evaluation of radiotherapy for the early and the inoperable stomach carcinoma. Nippon Acta Radiol 1971; 31: 505.

    PubMed  CAS  Google Scholar 

  38. Asakawa H, Takeda T: High energy x-ray therapy of gastric carcinoma. J Jap Soc Cancer Ther 1973; 8: 362.

    CAS  Google Scholar 

  39. Childs DS, Moertel CG, Holbrook MA, et al: Treatment of unresectable adenocarcinoma of the stomach with a combination of 5-fluorouracil and radiation. Am J Roentgenol 1986; 102: 541.

    Google Scholar 

  40. Falkson G: Halogenated pyrimidines as radiopotentiators in the treatment of stomach cancer. Prog Biochem Pharmacol 1965; 1: 695.

    Google Scholar 

  41. Falkson G, Falkson HC::Fluorouracil and radiotherapy in gastrointestinal cancer. Lancet 1969; 2: 1252.

    Article  PubMed  CAS  Google Scholar 

  42. Gastrointestinal Tumor Study Group: A combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 1982; 49: 1771.

    Article  Google Scholar 

  43. Gunderson LL, Hoskins B, Cohen AM, et al: Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 1983; 9: 965.

    Article  PubMed  CAS  Google Scholar 

  44. Haas L, Vaitkevicius V, Bukowski R, et al: Southwest Oncology Group (SWOG) pilot study of radiotherapy (R) + 5-fluorouracil (F) + Adriamycin = mitomycin C (M),in patients with minimal residual gastric cancer, abstract. Proc ASCO 1980;342:C-439.

    Google Scholar 

  45. Schein PS, Smith FP, Dritschillo A, et al: Phase I-II trial of combined modality FAM plus split-course radiation (FAM-RT-FAM) for locally advanced gastric and pancreatic cancer: a Mid-Atlantic Oncology Program Study, abstract. Proc ASCO 1983;126:C-491.

    Google Scholar 

  46. Lagunova IG, Cybulskij BA, Minerva OD, et al: Aufeinander folgende Strahlentherapie mit einem 24-meV Betatron and Chemotherapie mit Fluorouracil zur Behandlung von Kranken mit fortgeschrittenem Krebs des oberen Magenabschnittes. Radiobiol Radiother 1978; 13: 307.

    Google Scholar 

  47. Levi JA, Fox RM, Tattersall MH, et al: Analysis of a prospective randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 1986; 4: 1348.

    PubMed  CAS  Google Scholar 

  48. Gelber RD, Zelen M: Planning and reporting of clinical trials, in Calabresi PC, Schein PC, Rosenberg S (eds): Medical Oncology. New York, Macmillan, 1985, p 406.

    Google Scholar 

  49. Design and conduct of clinical trials, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology. Philadelphia, JB Lippincott, 1985, p 329.

    Google Scholar 

  50. Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 12: 2061.

    Google Scholar 

  51. Kolaric K, Potrebica V, Stanovnik M: Controlled phase III clinical study of 4-epidoxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology 1986; 43: 73.

    Article  PubMed  CAS  Google Scholar 

  52. Kovach JS, Moertel CG, Schutt AJ: A controlled trial of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 1974; 33: 563.

    Article  PubMed  CAS  Google Scholar 

  53. Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49: 1116.

    Article  Google Scholar 

  54. Wilke H, Preusser P, Fink U, et al: Preoperative “neoadjuvant” chemotherapy with etoposide/Adriamycin/cisplatin (EAP) in local advanced gastric cancer. Proc ECCO 1987; 4: 32.

    Google Scholar 

  55. Behre W, Brömsen J, Harstrick A, et al: Antitumor activity of anthracyclines in human gastric cancer xenografts depending on time scheduling. Blut 1987; 55: 224.

    Google Scholar 

Download references

Authors
  1. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Achterrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Poliwoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Gastroenterology and Oncology, General Hospital, Celle, Germany

    Jürgen Hotz M.D. (Professor of Medicine, Head) (Professor of Medicine, Head)

  2. Department of Surgery, Division of Abdominal and Transplantation Surgery, Medical University of Hannover, Hannover, Germany

    Hans-Joachim Meyer M.D. (Professor of Surgery) (Professor of Surgery)

  3. Department of Hematology/Oncology, Medical University of Hannover, Hannover, Germany

    H.-J. Schmoll M.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag New York, Inc.

About this paper

Cite this paper

Wilke, H., Preusser, P., Achterrath, W., Schmoll, HJ., Fink, U., Poliwoda, H. (1989). Polychemotherapy of Gastric Carcinoma. In: Hotz, J., Meyer, HJ., Schmoll, HJ. (eds) Gastric Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3636-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-3636-8_10

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-96955-8

  • Online ISBN: 978-1-4612-3636-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation